跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AT-351
首页
药物
AT-351
AT-351
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Anti-PD-L1/anti-CD47 bispecific antibody
申请人: BEIJING HANMI PHARMACEUTICAL CO LTD
优先权: 2017
CN
US
2 件公开
Reagent for diagnosing tumor, pharmaceutical composition, and screening method
申请人: TOKYO METROPOLITAN INST MEDICAL SCIENCE
优先权: 2012
US
3 件公开
Soluble immunoreactive Treponema pallidum TpN47 antigens
申请人: ROCHE DIAGNOSTICS GMBH
优先权: 2012
EP
US
3 件公开
POLYNUCLEOTIDES, POLYPEPTIDES ENCODED THEREBY, AND METHODS OF USING SAME FOR INCREASING ABIOTIC STRESS TOLERANCE, BIOMASS AND/OR YIELD IN PLANTS EXPRESSING SAME
申请人: EVOGENE LTD
优先权: 2008
EP
US
WO
7 件公开
Prevention of uveitis
申请人: KING S COLLEGE LONDON
优先权: 2003
US
Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
申请人: EMMANUEL EYAL
优先权: 2008
US
5 件公开
Tomato plants resistant to resistant breakthrough TSWV strains and corresponding resistance genes
申请人: VILMORIN
优先权: 2022
CN
用于药物递送装置的系统
申请人: 赛诺菲
优先权: 2018
CN
药物
反馈